GlassScriptPhysician profile
Anthony J Giampolo
NPI 1730304403
$142,587.27
in general payments reported to CMS, 2019-2025
24 companies · $41.50 in 2025
The $41.50 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138K · 2020: $773 · 2021: $3,375 · 2024: $217 · 2025: $41.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $150 · Food and Beverage: $67.36 · Education: $41.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $150.00 |
| Food and Beverage | $67.36 |
| Education | $41.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $133,950.00 | 2019 | |
| Partner Therapeutics, INC. | $3,375.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $587.45 | 2019 | |
| Genzyme Corporation | $547.80 | 2019 | |
| Amgen INC. | $538.95 | 2019-2020 | |
| Lilly USA, LLC | $451.27 | 2019-2020 | |
| Acorda Therapeutics, INC | $374.18 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $366.21 | 2019 | |
| Emd Serono, INC. | $357.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $324.81 | 2019 | |
| Genentech USA, INC. | $244.15 | 2019 | |
| Mallinckrodt Enterprises LLC | $229.16 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $150.00 | 2024 | Lumryz |
| Jazz Pharmaceuticals INC. | $142.32 | 2019-2025 | |
| Tanabe Pharma America, INC. | $125.86 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $121.91 | 2019 | |
| Adamas Pharmaceuticals, INC. | $120.43 | 2020 | |
| Alexion Pharmaceuticals, INC. | $119.99 | 2019 | |
| Amneal Pharmaceuticals LLC | $105.89 | 2020 | |
| Ucb, INC. | $85.78 | 2019 | |
| Allergan, INC. | $84.77 | 2020 | |
| Boston Scientific Corporation | $80.86 | 2019 | |
| Abbott Laboratories | $67.36 | 2024 | Dragonfly Opstar, Diamondback Coronary |
| Celgene Corporation | $35.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Giampolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.